Netherlands named as best base for international pharma companies
International pharma companies may do well to consider setting up shop in the Netherlands, according to data compiled by Mercator by Citco
Mercato's Pharmaceutical GEPM: Special Report - which provides insight into global entity portfolio management (GEPM) within the pharmaceuticals sector across more than 70 jurisdictions worldwide - calculates the ranking based on cost and time efficiencies.
Taking into account only time efficiencies, the US takes poll position whereas Luxembourg ranks first for its cost effectiveness. When combining these two metrics, however, the Netherlands scores the best.
The country's status as a European financial centre and its historic links to international trade are thought to have created an environment that allows multinational pharmaceutical companies to manage entities there with relative ease.
Using the same metrics, Singapore and Belgium also score highly, unlike Brazil, South Korea and China which have the lowest overall ranking.
The report also confirms that Europe remains the hub for a significant portion of pharmaceutical companies beyond North America, primarily led by eminent life sciences hubs in Switzerland, Germany and France; and India performs a similar role within the APAC region.
Mercator found the majority of the businesses it looked at are organisationally agile with robust business continuity plans in place, as demonstrated by their response to the COVID-19 pandemic.
However, Kariem Abdellatif, head of Mercator, warns that insights revealed by this report are "not a recommendation of where pharmaceutical multinationals should base their entities or subsidiaries as that will always be driven by demand and necessity".
Instead, Kariem advises forward-thinking multinational companies should embrace technology platforms that "let them do business seamlessly across borders and jurisdictions”.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance